Corporate Profile

SAB Biotherapeutics is a clinical-stage biopharmaceutical company leveraging its novel DiversitAb™ platform to produce a new class of specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors. By harnessing the native human antibody immune response, SAB’s platform enables a scalable and reliable production of these highly-efficacious polyclonal therapies with the potential to address the emergence, mutation, and diversity of modern health challenges including COVID-19, seasonal influenza, Type 1 diabetes, and cancers. The Company’s lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic for the treatment of COVID-19 advancing as part of the NIH’s ACTIV-2 protocol, and SAB-176, a multivalent, broadly neutralizing fully-human polyclonal antibody therapeutic candidate designed to bind to Type A and B viruses. Additional pre-clinical product candidates are in development for autoimmune diseases, including SAB-142 for Type 1 Diabetes and organ transplant induction/rejection, and SAB-181 for immune globulin (IgG) mediated diseases.

Data Provided by Refinitiv. Minimum 15 minutes delayed.